JP2023519891A5 - - Google Patents

Info

Publication number
JP2023519891A5
JP2023519891A5 JP2022558424A JP2022558424A JP2023519891A5 JP 2023519891 A5 JP2023519891 A5 JP 2023519891A5 JP 2022558424 A JP2022558424 A JP 2022558424A JP 2022558424 A JP2022558424 A JP 2022558424A JP 2023519891 A5 JP2023519891 A5 JP 2023519891A5
Authority
JP
Japan
Prior art keywords
approximately
compound
pharmaceutical composition
crystalline form
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024316 external-priority patent/WO2021195475A1/en
Publication of JP2023519891A publication Critical patent/JP2023519891A/ja
Publication of JP2023519891A5 publication Critical patent/JP2023519891A5/ja
Pending legal-status Critical Current

Links

JP2022558424A 2020-03-27 2021-03-26 置換ピリジノン-ピリジニル化合物のプロセス、組成物、および結晶形態 Pending JP2023519891A (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US202063000746P 2020-03-27 2020-03-27
US63/000,746 2020-03-27
US202063015241P 2020-04-24 2020-04-24
US63/015,241 2020-04-24
US202063018954P 2020-05-01 2020-05-01
US63/018,954 2020-05-01
US202063022301P 2020-05-08 2020-05-08
US202063022298P 2020-05-08 2020-05-08
US63/022,298 2020-05-08
US63/022,301 2020-05-08
US202063024160P 2020-05-13 2020-05-13
US63/024,160 2020-05-13
US202063053903P 2020-07-20 2020-07-20
US63/053,903 2020-07-20
US202063076689P 2020-09-10 2020-09-10
US63/076,689 2020-09-10
US202063126173P 2020-12-16 2020-12-16
US63/126,173 2020-12-16
US202063128523P 2020-12-21 2020-12-21
US63/128,523 2020-12-21
US202163136080P 2021-01-11 2021-01-11
US63/136,080 2021-01-11
US202163136967P 2021-01-13 2021-01-13
US63/136,967 2021-01-13
US202163138672P 2021-01-18 2021-01-18
US63/138,672 2021-01-18
US202163140116P 2021-01-21 2021-01-21
US63/140,116 2021-01-21
US202163149230P 2021-02-13 2021-02-13
US63/149,230 2021-02-13
PCT/US2021/024316 WO2021195475A1 (en) 2020-03-27 2021-03-26 Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds

Publications (2)

Publication Number Publication Date
JP2023519891A JP2023519891A (ja) 2023-05-15
JP2023519891A5 true JP2023519891A5 (cg-RX-API-DMAC7.html) 2024-03-29

Family

ID=77890611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558424A Pending JP2023519891A (ja) 2020-03-27 2021-03-26 置換ピリジノン-ピリジニル化合物のプロセス、組成物、および結晶形態
JP2022558423A Pending JP2023519890A (ja) 2020-03-27 2021-03-26 免疫状態の処置のためのmk2経路阻害剤の経口組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022558423A Pending JP2023519890A (ja) 2020-03-27 2021-03-26 免疫状態の処置のためのmk2経路阻害剤の経口組成物

Country Status (12)

Country Link
US (5) US12616696B2 (cg-RX-API-DMAC7.html)
EP (2) EP4132524A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023519891A (cg-RX-API-DMAC7.html)
KR (2) KR20220161390A (cg-RX-API-DMAC7.html)
CN (4) CN119454711A (cg-RX-API-DMAC7.html)
AU (2) AU2021244609A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019349A2 (cg-RX-API-DMAC7.html)
CA (2) CA3172088A1 (cg-RX-API-DMAC7.html)
IL (1) IL296054A (cg-RX-API-DMAC7.html)
MX (2) MX2022011755A (cg-RX-API-DMAC7.html)
PH (2) PH12022552263A1 (cg-RX-API-DMAC7.html)
WO (3) WO2021195507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296054A (en) * 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
WO2022020562A1 (en) * 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
KR20230112696A (ko) * 2020-11-23 2023-07-27 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 합성 방법
WO2022212489A1 (en) 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
US11685719B2 (en) 2021-07-09 2023-06-27 Xinthera, Inc. Pyridinone MK2 inhibitors and uses thereof
WO2023125708A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274B (zh) * 2022-01-06 2025-11-11 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
CN120076802A (zh) * 2022-09-30 2025-05-30 艾伯维公司 治疗化脓性汗腺炎的方法
CN118047757A (zh) * 2022-11-16 2024-05-17 上海美悦生物科技发展有限公司 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途
KR20240078816A (ko) 2022-11-28 2024-06-04 주식회사 엘지에너지솔루션 에이징 시스템
US20260217652A1 (en) 2023-01-13 2026-07-30 Shanghai Meiyue Biotech Development Co., Ltd. Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof
JP2026504073A (ja) * 2023-01-13 2026-02-03 プールベグ ファーマ(ユーケー) リミテッド がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
HUP0201261A3 (en) 1999-05-21 2003-12-29 Scios Inc Sunnyvale Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2002226911A1 (en) 2000-11-20 2002-06-03 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US7314752B2 (en) 2001-07-19 2008-01-01 Common Sense, Ltd. Secretion-monitoring article
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004024078A2 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
CN1976915A (zh) 2004-02-11 2007-06-06 史密丝克莱恩比彻姆公司 Hiv整合酶抑制剂
US7936407B2 (en) 2005-02-24 2011-05-03 Samsung Electronics Co., Ltd. Array substrate, method of manufacturing the same, display panel having the same, and liquid crystal display apparatus having the same
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
TW200740755A (en) 2005-07-13 2007-11-01 Bayer Cropscience Sa Dihalogenation of N,O-disubstituted hydroxypyridones and their uses
WO2007081901A2 (en) 2006-01-05 2007-07-19 The Scripps Research Institute Pyrimidinone derivatives as protein kinase inhibitors
PE20080150A1 (es) 2006-06-02 2008-04-11 Janssen Pharmaceutica Nv Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
AU2007272830B2 (en) 2006-07-14 2011-07-28 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
BRPI0720049A2 (pt) 2006-12-07 2014-01-07 Novartis Ag Derivados de piridina utilizados como inibidores de xiap
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
JP2010529129A (ja) 2007-06-06 2010-08-26 タイロジェネックス,インコーポレイテッド キナーゼ阻害剤化合物
PL2170864T3 (pl) 2007-07-17 2012-02-29 Bristol Myers Squibb Co Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
WO2010025202A1 (en) * 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
AU2010302420B2 (en) * 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
KR102313515B1 (ko) 2013-06-07 2021-10-14 어클라리스 쎄라퓨틱스, 인코포레이티드 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
WO2015161908A1 (en) * 2014-03-11 2015-10-29 Ludwig-Maximilians-Universität München Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections
CN114230571B (zh) * 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN111727042A (zh) 2017-12-06 2020-09-29 仁新医药私人有限公司 微管蛋白抑制剂
CN114206339A (zh) * 2019-07-31 2022-03-18 阿克拉瑞斯治疗股份有限公司 氘化mk2途径抑制剂及其使用方法
WO2021178449A1 (en) 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions

Similar Documents

Publication Publication Date Title
JP2025176008A5 (cg-RX-API-DMAC7.html)
IL322447A (en) Preparation of psilocybin, various polymorphic forms, intermediates, formulations and their use
EP3650439B1 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
JP2021536511A5 (cg-RX-API-DMAC7.html)
JP2023116503A5 (cg-RX-API-DMAC7.html)
JP2021530565A5 (cg-RX-API-DMAC7.html)
JP2021119136A5 (cg-RX-API-DMAC7.html)
JPWO2022138988A5 (cg-RX-API-DMAC7.html)
JP2024537795A5 (cg-RX-API-DMAC7.html)
JP2023522040A5 (cg-RX-API-DMAC7.html)
JP2018516883A5 (cg-RX-API-DMAC7.html)
EA025438B1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
JP2006519818A5 (cg-RX-API-DMAC7.html)
JPWO2021033729A5 (cg-RX-API-DMAC7.html)
JP2020502224A5 (cg-RX-API-DMAC7.html)
JP2025516683A5 (cg-RX-API-DMAC7.html)
JP2025515671A5 (cg-RX-API-DMAC7.html)
JP2016510767A5 (cg-RX-API-DMAC7.html)
JP2025148397A5 (cg-RX-API-DMAC7.html)
JP2009517353A5 (cg-RX-API-DMAC7.html)
JP2023530786A5 (cg-RX-API-DMAC7.html)
JP2023530785A5 (cg-RX-API-DMAC7.html)
JP2022540678A5 (cg-RX-API-DMAC7.html)
JP2025510826A5 (cg-RX-API-DMAC7.html)
KR100830002B1 (ko) 시부트라민의 무기산염